Cargando…

Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques

A nanoformulated myristoylated dolutegravir prodrug (NMDTG) was prepared using good laboratory practice protocols. Intramuscular injection of NMDTG (118 ± 8 mg/ml, 25.5 mg of DTG equivalents/kg of body weight) to three rhesus macaques led to plasma DTG levels of 86 ± 12 and 28 ± 1 ng/ml on days 35 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	McMillan, JoEllyn, Szlachetka, Adam, Slack, Lara, Sillman, Brady, Lamberty, Benjamin, Morsey, Brenda, Callen, Shannon, Gautam, Nagsen, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E., Fox, Howard S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740312/ https://www.ncbi.nlm.nih.gov/pubmed/29061742 http://dx.doi.org/10.1128/AAC.01316-17

Ejemplares similares

Creation of a long-acting nanoformulated dolutegravir
por: Sillman, Brady, et al.
Publicado: (2018)

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
por: Zhou, Tian, et al.
Publicado: (2017)

A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug
por: Kulkarni, Tanmay A., et al.
Publicado: (2020)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation
por: Ibrahim, Ibrahim M, et al.
Publicado: (2019)

Creation of a Long-Acting Nanoformulated 2′,3′-Dideoxy-3′-Thiacytidine
por: Guo, Dongwei, et al.
Publicado: (2017)

Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation
por: Deodhar, Suyash, et al.
Publicado: (2022)

Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir
por: Gautam, Nagsen, et al.
Publicado: (2021)

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine
por: Walimbwa, Stephen I., et al.
Publicado: (2019)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Dolutegravir Inhibition of Matrix Metalloproteinases Affects Mouse Neurodevelopment
por: Bade, Aditya N., et al.
Publicado: (2021)

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Bioequivalence of a Fixed-Dose Combination Tablet of the Complete Two-Drug Regimen of Dolutegravir and Rilpivirine for Treatment of HIV-1 Infection
por: Mehta, Rashmi, et al.
Publicado: (2018)

Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells
por: Kanmogne, Georgette D, et al.
Publicado: (2012)

Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals
por: Zhou, Tian, et al.
Publicado: (2018)

Nucleotide Prodrug Containing a Nonproteinogenic Amino Acid To Improve Oral Delivery of a Hepatitis C Virus Treatment
por: Feng, Joy Y., et al.
Publicado: (2018)

Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses
por: Good, Steven S., et al.
Publicado: (2021)

Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles
por: Cobb, Denise A., et al.
Publicado: (2021)

Safety, Pharmacokinetics, and Antiviral Activity of AT-527, a Novel Purine Nucleotide Prodrug, in Hepatitis C Virus-Infected Subjects with or without Cirrhosis
por: Berliba, Elina, et al.
Publicado: (2019)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19
por: Good, Steven S., et al.
Publicado: (2021)

Multimodal Theranostic Nanoformulations Permit Magnetic Resonance Bioimaging of Antiretroviral Drug Particle Tissue-Cell Biodistribution
por: Kevadiya, Bhavesh D., et al.
Publicado: (2018)

Nanoformulated Antiretroviral Therapy Attenuates Brain Metabolic Oxidative Stress
por: Montenegro-Burke, J. Rafael, et al.
Publicado: (2018)

Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors
por: Iampietro, M. Justin, et al.
Publicado: (2018)

Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy
por: Martinez-Skinner, Andrea L., et al.
Publicado: (2015)

Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors
por: Abbink, Peter, et al.
Publicado: (2018)

Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
por: Balkundi, Shantanu, et al.
Publicado: (2010)

Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents
por: Sorensen, Eric S., et al.
Publicado: (2020)

Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages
por: Araínga, Mariluz, et al.
Publicado: (2015)

Comparison of Subgenomic and Total RNA in SARS-CoV-2-Challenged Rhesus Macaques
por: Dagotto, Gabriel, et al.
Publicado: (2021)

Bridging Vaccine-Induced HIV-1 Neutralizing and Effector Antibody Responses in Rabbit and Rhesus Macaque Animal Models
por: Pollara, Justin, et al.
Publicado: (2019)

Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
por: Tostanoski, Lisa H., et al.
Publicado: (2021)

Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection
por: Jacob-Dolan, Catherine, et al.
Publicado: (2021)

Impact of T(h)1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques
por: Verma, Anil, et al.
Publicado: (2020)

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
por: Yu, Jingyou, et al.
Publicado: (2022)

Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys
por: Kang, Zi Han, et al.
Publicado: (2018)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from Malawi
por: Dickinson, Laura, et al.
Publicado: (2014)

Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
por: Krishnan, Preethi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2q0vsd50uki8b7rcvvq15e1h4i